Extracranial and transcranial colour-coded duplex sonography (TCCD) are used routinely in clinical practice to assess physiologic and pathologic arterial blood flow to the brain. Such investigations are straightforward, safe, and cost effective, and can be repeated frequently for patient follow-up. In addition, the portability of extracranial colour-coded duplex sonography and TCCD provides the option of bedside investigations, particularly useful for evaluation of the critically ill patient. However, duplex ultrasound can be hampered by insufficient acoustic penetration, an unfavourable insonation angle, or by conditions of low or no flow. Echocontrast agents capable of surviving pulmonary and capillary transit have been developed, and such agents increase the Doppler signal and, therefore, the success rate of neurosonographic investigations. Approximately 20% of TCCD studies involve poor insonation conditions and, therefore, the use of echocontrast agents is of particular interest for this application. Levovist® and SonoVue® are the two agents currently approved for use in neurosonography. Such agents have a relatively long-lasting effect (up to 7 min), and can be administered as a single injection or, alternatively, a fractionated injection protocol can be used, depending on the quality of the window.

Keywords:
Transcranial ultrasonography, Neurosonography, Cerebrovascular disease, Contrast agents
1.
Droste DW, Metz RJ: Clinical utility of echocontrast agents in neurosonology. Neurol Res 2004;26:754–759.
2.
Stolz EP, Kaps M: Ultrasound contrast agents and imaging of cerebrovascular disease. Semin Cerebrovasc Dis Stroke 2007;5:111–131.
3.
Kollar J, Schulte-Altedorneburg G, Sikula J, Fulesdi B, Ringelstein EB, Mehta V, et al: Image quality of the temporal bone window examined by transcranial Doppler sonography and correlation with postmortem computed tomography measurements. Cerebrovasc Dis 2004;17:61–65.
4.
Rosenkranz K, Zendel W, Langer R, Heim T, Schubeus P, Scholz A, et al: Contrast-enhanced transcranial Doppler US with a new transpulmonary echo contrast agent based on saccharide microparticles. Radiology 1993;187:439–443.
5.
Gebel M, Caselitz M, Bowen-Davies PE, Weber S: A multicenter, prospective, open label, randomized, controlled phase IIIb study of SH U 508 A (Levovist) for Doppler signal enhancement in the portal vascular system. Ultraschall Med 1998;19:148–156.
6.
Droste DW, Jürgens R, Nabavi DG, Schuierer G, Weber S, Ringelstein EB: Echocontrast-enhanced ultrasound of extracranial internal carotid artery high-grade stenosis and occlusion. Stroke 1999;30:2302–2306.
7.
Droste DW, Jürgens R, Weber S, Tietje R, Ringelstein EB: Benefit of echocontrast-enhanced transcranial color-coded duplex ultrasound in the assessment of intracranial collateral pathways. Stroke 2000;31:920–923.
8.
Schminke U, Motsch L, Bleiss A, von Smekal U, Griewing B, Kessler C: Continuous administration of contrast medium for transcranial colour-coded sonography. Neuroradiology 2001;43:24–28.
9.
Bokor D: Diagnostic efficacy of SonoVue. Am J Cardiol 2000;86:19G–24G.
10.
Droste DW, Llull JB, Pezzoli C, Bogdahn U, Kaps M: SonoVue® (BR1), a new long-acting echocontrast agent, improves transcranial colour-coded duplex ultrasonic imaging. Cerebrovasc Dis 2002;14:27–32.
11.
European Agency for the Evaluation of Medicinal Products: Public statement on SonoVue (sulphur hexafluoride): new contraindication in patients with heart disease; restriction of use to non-cardiac imaging. 2004. http://www.emea.eu.int/pdfs/human/press/pus/021204en.pdf.
12.
European Agency for the Evaluation of Medicinal Products: Questions and answers on SonoVue. 2004. http://www.emea.eu.int/humandocs/Humans/EPAR/sonovue/list.htm.
13.
Correas JM, Burns PN, Lai X, Qi X: Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR1. Invest Radiol 2000;35:72–79.
14.
Gahn G, Gerber J, Hallmeyer S, Hahn G, Ackerman RH, Reichmann H, et al: Contrast-enhanced transcranial color-coded duplex sonography in stroke patients with limited bone windows. Am J Neuroradiol 2000;21:509–514.
15.
Zunker P, Wilms H, Brossmann J, Georgiadis D, Weber S, Deuschl G: Echo contrast-enhanced transcranial ultrasound: frequency of use, diagnostic benefit, and validity of results compared with MRA. Stroke 2003;33:2600–2603.
16.
Hansberg T, Wong KS, Droste DW, Ringelstein EB: Effects of the ultrasound contrast-enhancing agent Levovist on the detection of intracranial arteries and stenoses in Chinese by transcranial Doppler ultrasound. Cerebrovasc Dis 2003;14:105–108.
17.
Droste DW, Boehm T, Ritter MA, Dittrich R, Ringelstein EB: Benefit of echocontrast-enhanced transcranial arterial color-coded duplex ultrasound. Cerebrovasc Dis 2005;20:332–336.
18.
Connors JJ III, Sacks D, Furlan AJ, Selman WR, Russell EJ, Stieg PE, et al: Training, competency, and credentialing standards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: a joint statement from the American Academy of Neurology, the American Association of Neurological Surgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Society of Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section, and the Society of Interventional Radiology. Neurology 2005;64:190–198.
19.
Baumgartner RW, Arnold M, Gonner F, Staikow I, Herrmann C, Rivoir A, et al: Contrast-enhanced transcranial color-coded duplex sonography in ischemic cerebrovascular disease. Stroke 1997;28:2473–2478.
20.
Gerriets T, Seidel G, Fiss I, Modrau B, Kaps M: Contrast-enhanced transcranial color-coded duplex sonography: efficiency and validity. Neurology 1999;52:1133–1137.
21.
Gerriets T, Goertler M, Stolz E, Postert T, Sliwka U, Schlachetzki F, et al: Feasibility and validity of transcranial duplex sonography in patients with acute stroke. J Neurol Neurosurg Psychiatr 2002;73:17–20.
22.
Goertler M, Kross R, Baeumer M, Jost S, Grote R, Weber S, et al: Diagnostic impact and prognostic relevance of early contrast-enhanced transcranial color-coded duplex sonography in acute stroke. Stroke 1998;29:955–962.
23.
Nabavi DG, Droste DW, Kemény V, Schulte-Altedorneburg G, Weber S, Ringelstein EB: Potential and limitations of echocontrast-enhanced ultrasonography in acute stroke patients: a pilot study. Stroke 1998;29:949–954.
24.
Postert T, Braun B, Meves S, Koster O, Przuntek H, Weber S, et al: Contrast-enhanced transcranial color-coded sonography in acute hemispheric brain infarction. Stroke 1999;30:1819–1826.
25.
Wessels T, Bozzato A, Mull M, Klotzsch C: Intracranial collateral pathways assessed by contrast-enhanced three-dimensional transcranial color-coded sonography. Ultrasound Med Biol 2004;30:1435–1440.
26.
Becker G, Lindner A, Bogdahn U: Imaging of the vertebrobasilar system by transcranial color-coded real-time sonography. J Ultrasound Med 1993;12:395–401.
27.
Droste DW, Nabavi DG, Kemény V, Schulte-Altedorneburg G, Ritter M, Weber S, et al: Echocontrast enhanced transcranial color-coded duplex offers improved visualization of the vertebrobasilar system in patients with bad examination conditions. Acta Neurol Scand 1998;98:193–199.
28.
Stolz E, Nuckel M, Mendes I, Gerriets T, Kaps M: Vertebrobasilar transcranial color-coded duplex ultrasonography: improvement with echo enhancement. Am J Neuroradiol 2002;23:1051–1054.
29.
Fürst G, Sitzer M, Hofer M, Steinmetz H, Hackländer T, Mödder U: Kontrastmittelverstärkte farbkodierte Duplexsonographie hochgradiger Karotisstenosen. Ultraschall Med 1995;16:140–144.
30.
Gahn G, Hahn G, Hallmeyer-Elgner S, Kunz A, Straube T, Bourquain H, et al: Echo-enhanced transcranial color-coded duplex sonography to study collateral blood flow in patients with symptomatic obstructions of the internal carotid artery and limited acoustic bone windows. Cerebrovasc Dis 2002;11:107–112.
31.
Giannoni MF, Bilotta F, Fiorani L, Zaccaria A, Rizzo L, Fiorani B, et al: Ultrasound echo-enhancers in the evaluation of endovascular prostheses. Cardiovasc Surg 1999;7:532–538.
32.
Hofstee DJ, Hoogland PH, Schimsheimer RJ, de Weerd AW: Contrast enhanced color duplex for diagnosis of subtotal stenosis or occlusion of the internal carotid artery. Clin Neurol Neurosurg 2000;102:9–12.
33.
Sitzer M, Rose G, Fürst G, Siebler M, Steinmetz H: Characteristics and clinical value of an intravenous echo-enhancement agent in evaluation of high-grade internal carotid stenosis. J Neuroimaging 1997;7(suppl 1):22–25.
34.
Harrer JU, Popescu O, Henkes HH, Klotzsch C: Assessment of dural arteriovenous fistulae by transcranial color-coded duplex sonography. Stroke 2005;36:976–979.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.